Skip to main content
. 2022 Feb 8;13:830292. doi: 10.3389/fimmu.2022.830292

Table 5.

Summary of preclinical studies on CAR-T cells engineered to overcome the immunosuppressive effect of TAMs.

Targeted antigen Type of cancer Reference
mFRβ Ovarian cancer (203)
Ovarian cancerMelanomaColon adenocarcinoma (204)
CD123 Hodgkin lymphoma (205)
CD47 & TAG-72 Ovarian cancer (207)
CD47 MelanomaColon adenocarcinoma (210)